Read by QxMD icon Read

Infectious Diseases and Therapy

Sarah J Pugh, Mark A Fletcher, Apostolos Charos, Lynda Imekraz, Matt Wasserman, Raymond Farkouh
INTRODUCTION: To evaluate the expected impact of the Algeria national immunization program (NIP) and potential impact for a Tunisia NIP, this study assessed the public health and economic value of vaccination, through a cost-effectiveness analysis, for a PCV13 or PCV10 NIP, compared with no vaccination. METHODS: A decision-analytic model was programmed in Microsoft Excel™ and adapted to evaluate the clinical and economic outcomes of PCV vaccination. Assuming a steady state, the model estimated invasive pneumococcal disease (IPD; bacteremia and meningitis), all-cause pneumonia (inpatient and outpatient), and all-cause otitis media cases as well as the associated costs from a payer perspective...
December 11, 2018: Infectious Diseases and Therapy
Claris Shoko, Delson Chikobvu, Pascal O Bessong
In the original publication, the following text was missing from the beginning of the Methods section in the main text "This study uses similar methods to those previously published.
December 6, 2018: Infectious Diseases and Therapy
Alaa Badawi, Paul Arora, Darren Brenner
INTRODUCTION: Lyme disease-also known as Lyme borreliosis (LB)-is the most common vector-borne disease in North America and Europe. It may result in substantial morbidity, primarily from persistent Lyme arthritis (LA) that-although treatable-can develop into antibiotic-refractory LA (A-RLA). The aim of this study is to systematically review and evaluate a range of biomarkers for their potential predictive value in the development of A-RLA. METHODS: We conducted a systematic review of studies examining biomarkers among patients with A-RLA from MEDLINE via OVID, EMBASE and Web of Science databases and identified a total of 26 studies for qualitative analysis...
November 30, 2018: Infectious Diseases and Therapy
Yamuna Devi Bakthavatchalam, Ravikar Ralph, Balaji Veeraraghavan, Priyanka Babu, Elakkiya Munusamy
INTRODUCTION: Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia may result in clinical failure of vancomycin therapy, together with prolonged infection and hospitalization. This clinical problem has resulted in a search for more effective treatment options. The current study was designed to further investigate the synergistic effect of oxacillin plus vancomycin against methicillin-resistant S. aureus (MRSA) and hVISA using checkerboard and time-kill assays...
November 21, 2018: Infectious Diseases and Therapy
Matt D Wasserman, Heather L Sings, Michele R Wilson, Maarten J Postma, Marie-Claude Breton, Cheryl McDade, Raymond A Farkouh
No abstract text is available yet for this article.
November 20, 2018: Infectious Diseases and Therapy
Michele R Wilson, Matt Wasserman, Taj Jadavji, Maarten Postma, Marie-Claude Breton, Francois Peloquin, Stephanie R Earnshaw, Cheryl McDade, Heather L Sings, Raymond Farkouh
No abstract text is available yet for this article.
November 8, 2018: Infectious Diseases and Therapy
Ashleigh McGirr, Shehzad M Iqbal, Jan Olbrecht, Lijoy Varghese
No abstract text is available yet for this article.
November 8, 2018: Infectious Diseases and Therapy
Claris Shoko, Delson Chikobvu, Pascal O Bessong
INTRODUCTION: Improvement of health in human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients on antiretroviral therapy (ART) is characterised by an increase in CD4 cell counts and a decrease in viral load to undetectable levels. In modelling HIV/AIDS progression in patients, researchers mostly deal with either viral load levels only or CD4 cell counts only, as they expect these two variables to be collinear. In this study, both variables will be in one model...
November 2, 2018: Infectious Diseases and Therapy
Georgios Sogkas, Diana Ernst, Faranaz Atschekzei, Alexandra Jablonka, Reinhold E Schmidt, Georg M N Behrens, Matthias Stoll
INTRODUCTION: The way syphilis affects the immunologic and virologic parameters of a human immunodeficiency virus (HIV) infection remains controversial. The aim of this study was to investigate the impact of syphilis infection on lymphocyte and lymphocyte subset counts as well as viral load in HIV-infected patients. METHODS: All HIV-infected patients attending the outpatient clinic for infectious diseases of Hannover Medical University Hospital diagnosed with syphilis between 2009 and 2016 were retrospectively evaluated for changes in total lymphocyte, B cell, CD3+ T cell, CD4+ and CD8+ T cell counts as well as in HIV viral load...
October 30, 2018: Infectious Diseases and Therapy
Tram T Tran, Darshan Mehta, Federico Mensa, Caroline Park, Yanjun Bao, Yuri Sanchez Gonzalez
INTRODUCTION: Chronic hepatitis C (CHC) infection is associated with extrahepatic manifestations (EHMs) which can affect renal, cardiovascular and other comorbidities. The effect of CHC treatment with short-duration regimens on these EHMs is not well defined. Hence, we examined longitudinal estimated glomerular filtration rate (eGFR), triglycerides and glucose values to assess the impact of short-duration CHC therapy on renal, cardiovascular and metabolic diseases, respectively. METHODS: We conducted analyses of all patients without cirrhosis treated with glecaprevir and pibrentasvir (G/P) for 8 weeks in two phase 3 clinical trials...
October 27, 2018: Infectious Diseases and Therapy
Sarah C J Jorgensen, Michael J Rybak
No abstract text is available yet for this article.
October 3, 2018: Infectious Diseases and Therapy
Richard G Wunderink, Evangelos J Giamarellos-Bourboulis, Galia Rahav, Amy J Mathers, Matteo Bassetti, Jose Vazquez, Oliver A Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N Dudley, Keith S Kaye
INTRODUCTION: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 to evaluate the efficacy/safety of meropenem-vaborbactam monotherapy versus best available therapy (BAT) for CRE. METHODS: A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, complicated urinary tract infection/acute pyelonephritis) were randomized, and 47 with confirmed CRE infection formed the primary analysis population (microbiologic-CRE-modified intent-to-treat, mCRE-MITT)...
October 1, 2018: Infectious Diseases and Therapy
Kerstin J Olbrich, Dirk Müller, Sarah Schumacher, Ekkehard Beck, Kinga Meszaros, Florian Koerber
INTRODUCTION: Invasive meningococcal disease (IMD, septicaemia and/or meningitis) has a severe acute and long-term burden: 5-10% of patients die within 48 h, and long-term sequelae have been reported in 10-20% of survivors. Health-related quality of life (HRQoL) is increasingly but inconsistently assessed. METHODS: A systematic literature review on Neisseria meningitidis IMD sequelae and HRQoL in survivors of all ages and their caregivers, including family, was conducted for high-income countries from 2001 to 2016 (in Medline and Embase, following Cochrane and PRISMA guidelines)...
September 28, 2018: Infectious Diseases and Therapy
Gregory J Moran, Carisa De Anda, Anita F Das, Sinikka Green, Purvi Mehra, Philippe Prokocimer
INTRODUCTION: Injection drug users (IDUs) often develop acute bacterial skin and skin structure infections (ABSSSI) and use emergency departments as their primary source for medical care. METHODS: A post hoc subgroup analysis of two randomized trials examined the efficacy and safety of tedizolid in the treatment of ABSSSI in IDUs. IDUs (n = 389) were identified from two pooled phase 3 trials (NCT01170221, NCT01421511) in patients with ABSSSI (n = 1333). Patients were randomly assigned to tedizolid phosphate (200 mg once daily, 6 days) or linezolid (600 mg twice daily, 10 days)...
September 21, 2018: Infectious Diseases and Therapy
Kimberly C Claeys, Evan J Zasowski, Abdalhamid M Lagnf, Noor Sabagha, Donald P Levine, Susan L Davis, Michael J Rybak
INTRODUCTION: Acute bacterial skin and skin structure infections (ABSSSIs) represent a large burden to the US healthcare system. There is little evidence-based guidance regarding the appropriate level of care for ABSSSIs. This study aimed to develop a prediction model and risk-scoring tool to determine appropriate levels of care. METHODS: This was a single-center observational cohort study of adult patients treated for ABSSSIs from 2012 to 2015 at the Detroit Medical Center...
December 2018: Infectious Diseases and Therapy
Natalia V Dmitrieva, Galina A Klyasova, Natalia V Bakulina, Marina A Sukhina, Sergey V Zhuravel, Elena A Belousova, Vladimir T Ivashkin, Sergey V Goryunov, Elena A Prokhorovich, Tatyana R Kameneva, Aleksey A Samsonov, Andrey V Yakovenko, Stanislav V Kazakov
INTRODUCTION: The objective of the study was to evaluate the prevalence of Clostridium difficile-associated diarrhoea (CDAD) among hospitalised patients with antibiotic-associated diarrhoea (AAD) in general and by specific types of medical care and hospital units. METHODS: A prospective, cross-sectional, non-interventional, multicentre study. The main inclusion criteria were: patient age ≥ 18 years, hospital stay of at least 48 h, current antibiotic therapy or antibiotic therapy within the previous 30 days, loose stools (Bristol stool types 5-7 and stool frequency ≥ 3 within ≤ 24 consecutive hours or exceeding normal for the patient) and signed informed consent form...
September 10, 2018: Infectious Diseases and Therapy
Maria C Leoni, Andrew Ustianowski, Hamzah Farooq, Joop E Arends
Elimination of the three blood-borne viruses-human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV)-as public health issues may be plausible in the near future. Spectacular advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies are available for all three infections. Effective disease control, laid out by WHO global strategies, is currently feasible for all three viruses. However, for worldwide elimination of these viruses, effective vaccines are required that are currently only available for HBV...
September 4, 2018: Infectious Diseases and Therapy
Patricia A M Kracht, Faydra I Lieveld, Linde M Amelung, Carina J R Verstraete, Eveline P Mauser-Bunschoten, Joep de Bruijne, Peter D Siersema, Andy I M Hoepelman, Joop E Arends, Karel J van Erpecum
INTRODUCTION: Pegylated interferon-based therapy for hepatitis C virus (HCV) negatively impacts nutritional state and patient-reported outcomes (PROs) such as health-related quality of life (HRQL). Clinical trials with direct-acting antivirals (DAAs) report significant PRO improvement but real-world data are still scarce. METHODS: Prospective cohort study recruiting HCV patients treated with DAAs in 2015-2016. Data at baseline, end of treatment (EOT) and 12 weeks thereafter (FU12 ) included: patient-reported medication adherence; SF-36; Karnofsky Performance Status; paid labour productivity; physical exercise level; nutritional state [by body mass index (BMI) and Jamar hand grip strength (HGS)] and Beliefs about Medicines Questionnaire...
September 2018: Infectious Diseases and Therapy
Jean-Pierre Gangneux, Jean El Cheikh, Raoul Herbrecht, Ibrahim Yakoub-Agha, Jean-Baptiste Quiniou, Denis Caillot, Mauricette Michallet
INTRODUCTION: The frequency of invasive fungal diseases (IFDs) has increased in recent years. Within a context where both treatments and guidelines are fast evolving, we aim to shed new light on IFD management in hematologic departments in France. METHODS: A multicenter cross-sectional observational study was prospectively conducted in 24 French centers in September and October 2013. RESULTS: Four hundred ninety-four hospitalized children and adult patients suffering from hematologic malignancy were enrolled: 147 (30%) were allogeneic hematopoietic stem cell transplant (HSCT) recipients, 131 (27%) were patients with acute myeloblastic leukemia or myelodysplastic syndrome (MDS), 71 (14%) were patients with acute lymphoblastic leukemia who did not undergo allogeneic HSCT, and the 145 (29%) remaining patients did not belong to the three above groups...
September 2018: Infectious Diseases and Therapy
Sergey Shlyapnikov, Arturo Jauregui, Nana N Khachatryan, Asok Kurup, Javier de la Cabada-Bauche, Hoe N Leong, Li Li, Mark H Wilcox
INTRODUCTION: Tedizolid phosphate 200 mg, once daily for 6 days, has recently been approved for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs) in several countries; however, clinical experience in real-life settings is currently limited. Here, we report on the use of tedizolid with an extended treatment duration for complex and severe ABSSSIs in real-world clinical settings. METHODS: Two patients with cellulitis and two patients with surgical site infection (SSI), aged 26-60 years, were treated with tedizolid phosphate 200 mg, intravenous/oral (IV/PO) or IV only, once daily at four different institutions...
July 12, 2018: Infectious Diseases and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"